|Appears in Collections:||Computing Science and Mathematics Conference Papers and Proceedings|
|Peer Review Status:||Refereed|
|Title:||ASYMS-SERAT: A Side-Effect Risk Assessment Tool to Predict Chemotherapy Related Toxicity in Patients with Cancer Receiving Chemotherapy|
Londral, Ana Rita
|Citation:||Cowie J, Swingler K, Leadbetter C, Maguire R, McCall K & Kearney N (2008) ASYMS-SERAT: A Side-Effect Risk Assessment Tool to Predict Chemotherapy Related Toxicity in Patients with Cancer Receiving Chemotherapy In: Azevedo Luis, Londral Ana Rita (ed.) Proceedings of the First International Conference on Health Informatics, HEALTHINF 2008, Funchal, Madeira, Portugal, January 28-31, 2008, Volume 2, Setubal, Portugal: INSTICC - Institute for Systems and Technologies of Information, Control and Communication. HEALTHINF - International Conference on Health Informatics 2008, Madeira, Portugal, pp. 225-230.|
|Conference Name:||HEALTHINF - International Conference on Health Informatics 2008|
|Conference Location:||Madeira, Portugal|
|Abstract:||Patients undergoing chemotherapy want specific information on potential toxicities of their treatment. Such information includes what side-effects they are likely to experience, how severe these side-effects will be, how long they will experience them for, and the best ways of managing them. As well as improving the experiences of patients, information about potential side-effects may also be of significant benefit clinically, as patients who are ‘at risk’ of developing certain toxicities may be identified, facilitating more targeted, cost-effective interventions. This paper describes research which uses risk modelling techniques for identifying patterns in patient side-effect data to aid in predicting side-effects patients are likely to experience. Through analysis of patient data, a patient can receive information specific to the symptoms they are likely to experience. A user-friendly software tool SERAT (Side-Effect Risk Assessment Tool) has been developed, which presents side-effect information to the patients both at the start of treatment and reviews and monitors predictions with each new cycle of chemotherapy received.|
|Rights:||ASyMS(c); The publisher has not responded to our queries therefore this work cannot be made publicly available in this Repository. Please use the Request a Copy feature at the foot of the Repository record to request a copy directly from the author; you can only request a copy if you wish to use this work for your own research or private study.|
|healthinfopaper13aug.pdf||157.54 kB||Adobe PDF||Under Embargo until 31/12/2999 Request a copy|
Note: If any of the files in this item are currently embargoed, you can request a copy directly from the author by clicking the padlock icon above. However, this facility is dependant on the depositor still being contactable at their original email address.
This item is protected by original copyright
Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
If you believe that any material held in STORRE infringes copyright, please contact email@example.com providing details and we will remove the Work from public display in STORRE and investigate your claim.